Table 1

Patient characteristics and response summary. Cy, cyclophosphamide; Vinc, vincristine; Pred, prednisone; Etop, etoposide; Peg, pegylated asparaginase; Mito, mitoxantrone; CR1, first complete remission; MRD, minimal residual disease as assessed by deep sequencing (see Supplementary Materials); Allo-SCT, allogeneic stem cell transplant; FISH, fluorescence in situ hybridization. All patients were treated with cyclophosphamide before T cell infusion, either 1.5 g/m2 (MSK-ALL04, MSK-ALL05, and MSK-ALL06) or 3.0 g/m2 (MSK-ALL01 and MSK-ALL03).

Patient
ID*
Age
(years)
FISH/cytogeneticsInitial
therapy
Duration
of CR1
Salvage
therapy
Disease response
to salvage
therapy
Disease
response to
T cell therapy
SteroidsOutcome
MSK-ALL0166Normal
karyotype
Mito/Cy→
Vinc/Pred→Cy→
Etop/Cy
27 weeksVinc/Pred/PegMRD+MRDNAllo-SCT
MSK-ALL0356Normal
karyotype
Hyper-CVAD45 weeksInotuzumab
ozogamicin→Vinc/
Pred/Peg
MRDMRDNAllo-SCT
MSK-ALL0459t(9;11), 9p21
deletion
ECOG2993 (24)5 weeksVinc/PredRefractory
disease,
63% blasts
in BM
MRDYIneligible
for Allo-SCT,
relapse
90 days
MSK-ALL05589p21 deletionECOG299328 weeksHIDAC/MitoRefractory
disease,
70% blasts
in BM
MRDYAllo-SCT
MSK-ALL0623Normal
karyotype
NYII (25)34 monthsModified NYII
consolidation I (25)
MRD+MRDNAllo-SCT

*MSK-ALL02 patient was removed from the study before the planned T cell infusion because he deferred T cell infusion for an allo-SCT.

†Disease status within 1 week of infusion with CD19-targeted T cells.

‡This patient’s T cells were harvested while in remission. All other patients listed had their T cells harvested while they had relapsed disease.